SCHEMBL2815380

SCHEMBL2815380

COc1ccc(Cc2nc(C(N)=O)c(NC(=O)Nc3ccc(C(C)C)cc3)[nH]2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
RAB9A P51151 3/20 0.57
SAE1 Q9UBE0 1/20 0.52
UBA2 Q9UBT2 1/20 0.52
RET P07949 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
POLB P06746 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 2/20 0.43
FPR2 P25090 1/20 0.43
NTRK1 P04629 1/20 0.42
PDE2A O00408 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17957262 0.91 MEN1 (0.58) MEN1KMT2ARAB9ASAE1UBA2
SCHEMBL2814139 0.90 KMT2A (0.44) MEN1KMT2ARAB9ASAE1UBA2
SCHEMBL2814136 0.89 KMT2A (0.42) MEN1KMT2ARAB9ASAE1UBA2
SCHEMBL2816165 0.87 COPS5 (0.43) MEN1KMT2ARAB9ACA12CA1
SCHEMBL13132948 0.86 MAPT (0.43) MEN1KMT2ARAB9ACA12CA1
SCHEMBL13132987 0.85 SAE1 (0.51) MEN1KMT2ARAB9ASAE1UBA2
SCHEMBL2816533 0.85 SAE1 (0.48) MEN1KMT2ARAB9ASAE1UBA2
SCHEMBL17957263 0.85 MEN1 (0.55) MEN1KMT2ARAB9ASAE1UBA2
SCHEMBL2812896 0.84 NPC1 (0.55) MEN1KMT2ARAB9ASAE1UBA2
SCHEMBL2816512 0.83 FBP1 (0.46) MEN1KMT2ARAB9ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2193122-B1 IMIDAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2016-08-03 EP claimed
US-20100249132-A1 IMIDAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-30 US disclosed
US-20100249132-A1 IMIDAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249132-A1 IMIDAZOLE DERIVATIVES SDHA, SDHB, TPD52L2 MEN1 171/4885KMT2A 1034/4885RAB9A 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.